Bortezomib (Velcade)
Sponsors
Janssen Research & Development, LLC, Dana-Farber Cancer Institute, Medical University of Vienna, University of Arkansas, Weill Medical College of Cornell University
Conditions
Hematologic MalignanciesLymphoplasmacytic LymphomaMALT LymphomaMultiple MyelomaMyeloma MultipleNon Hodgkin's Follicular LymphomaWaldenstrom's Macroglobulinemia
Phase 1
Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation
CompletedNCT00369226
Start: 2006-08-31End: 2011-09-30Updated: 2013-07-25
Panobinostat/Velcade in Multiple Myeloma
TerminatedNCT00891033
Start: 2009-04-30End: 2013-08-31Updated: 2015-02-23
Phase 2
Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia
CompletedNCT00142129
Start: 2003-12-31End: 2007-06-30Target: 27Updated: 2011-06-27
Velcade in MALT Lymphoma Patients
CompletedNCT00373906
Target: 16Updated: 2013-11-27
Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
TerminatedNCT01062230
Start: 2010-01-31End: 2013-08-31Updated: 2015-04-06
VELCADE® Plus Rituximab in Non Hodgkin's Follicular Lymphoma
CompletedNCT01830465
Start: 2006-08-31End: 2011-05-31Updated: 2013-04-12
Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure
RecruitingNCT07085728
Start: 2026-03-05End: 2038-09-11Target: 74Updated: 2026-09-14
Phase 3
Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma
CompletedNCT00103506
Start: 2004-12-31End: 2014-06-30Updated: 2015-10-19
Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma
CompletedNCT01146834
Start: 2011-03-31End: 2019-02-04Updated: 2019-12-27